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A B S T R A C T
Background
Crohn’s disease (CD) is a chronic relapsing inflammatory condition. Many patients fail to achieve remission with medical management
and require surgical interventions. Purine analogues have been used tomaintain surgically-induced remission inCD, but the effectiveness
of these agents is unclear.
Objectives
The objectives were to evaluate the efficacy and safety of purine analogues for maintenance of surgically-induced remission in CD.
Search methods
We searched the following databases from inception to 30 April 2014: PubMed, MEDLINE, EMBASE, CENTRAL, and the Cochrane
Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Trials Register). We also searched the reference lists of
all included studies, and contacted personal sources and drug companies to identify additional studies. The searches were not limited
by language.
Selection criteria
Randomised controlled trials (RCTs) that compared purine analogues to placebo or another intervention, with treatment durations of
at least six months were considered for inclusion. Participants were patients of any age with CD in remission following surgery.
Data collection and analysis
Two authors independently assessed trial eligibility and extracted data. Methodological quality was assessed using the Cochrane risk of
bias tool. The primary outcome measures were clinical and endoscopic relapse as defined by the primary studies. Secondary outcomes
included adverse events, withdrawal due to adverse events and serious adverse events. Data were analysed on an intention-to-treat basis
where patients with missing final outcomes were assumed to have relapsed. We calculated the risk ratio (RR) and corresponding 95%
confidence interval (95% CI) for dichotomous outcomes. The Chi2 and I2 statistics were used to assess heterogeneity. The overall
quality of the evidence supporting the primary outcomes and selected secondary outcomes was assessed using the GRADE criteria.
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Main results
Seven RCTs (n = 584 patients) were included in the review. Three studies compared azathioprine to 5-aminosalicylic acid (5-ASA). One
small study compared azathioprine to both 5-ASA and adalimumab. One study compared azathioprine to placebo and another study
compared 6-mercaptopurine to 5-ASA and placebo. One small study compared azathioprine to infliximab. Three studies were judged
to be at low risk of bias. Four studies were judged to be at high risk of bias due to blinding. The study (n = 22) comparing azathioprine
to infliximab found that the effects on the proportion of patients who had a clinical (RR 2.00, 95% CI 0.21 to 18.98) or endoscopic
relapse (RR 4.40, 95% CI 0.59 to 3.07) were uncertain. One study (n = 33) found decreased clinical (RR 5.18, 95% CI 1.35 to 19.83)
and endoscopic relapse (RR 10.35, 95% CI 1.50 to 71.32) rates favouring adalimumab over azathioprine. A pooled analysis of two
studies (n = 168 patients) showed decreased clinical relapse rates at one or two years favouring purine analogues over placebo. Forty-
eight per cent of patients in the purine analogue group experienced a clinical relapse compared to 63% of placebo patients (RR 0.74,
95% CI 0.58 to 0.94). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to
high risk of bias (one study was single-blind) and sparse data (93 events). One study (87 patients) found a reduction in endoscopic
relapse rates favouring 6-mercaptopurine over placebo. Seventeen per cent of 6-mercaptopurine patients had an endoscopic relapse at
two years compared to 42% of placebo patients (RR 0.40, 95% CI 0.19 to 0.83). A GRADE analysis indicated that the overall quality
of the evidence for this outcome was low due to very sparse data (25 events). A pooled analysis of five studies (n = 425 patients) showed
no difference in clinical relapse rates at one or two years between purine analogues and 5-ASA agents. Sixty-three per cent of patients
in the purine analogues group experienced a clinical relapse compared to 54% of 5-ASA patients (RR 1.15, 95% CI 0.99 to 1.34). A
GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to high risk of bias (two
open-label studies), sparse data (249 events) and moderate heterogeneity (I2 = 45%). There was no difference in endoscopic relapse
at 12 months between azathioprine and 5-ASA (RR 0.78, 95% CI 0.52 to 1.17; 1 study, 35 patients). A GRADE analysis indicated
that the overall quality of the evidence for this outcome was very low due to high risk of bias (open-label study) and very sparse data
(26 events). There was a reduction in endoscopic relapse at 24 months favouring 6-mercaptopurine over 5-ASA patients. Seventeen
per cent of 6-mercaptopurine patients had an endoscopic relapse compared to 48% of 5-ASA patients (RR 0.36, 95% CI 0.18 to
0.72; 1 study, 91 patients). A GRADE analysis indicated that the overall quality of the evidence for this outcome was low due to very
sparse data (29 events). Adverse events that required withdrawal were more common in the purine analogue group compared to 5-ASA.
Twenty per cent of patients in the purine analogue group withdrew due to adverse events compared to 10% of 5-ASA patients (RR
2.07, 95% CI 1.26 to 3.39; 5 studies, 423 patients).The results for withdrawal due to adverse events between purine analogues and
placebo or for other comparisons were uncertain. Commonly reported adverse events across all studies included leucopenia, arthralgia,
abdominal pain or severe epigastric intolerance, elevated liver enzymes, nausea and vomiting, pancreatitis, anaemia, exacerbation of
Crohn’s disease, nasopharyngitis, and flatulence.
Authors’ conclusions
Purine analogues may be superior to placebo for maintenance of surgically-induced remission in patients with CD, although this is
based on two small studies. The results for efficacy outcomes between purine analogues and 5-ASA agents were uncertain. However,
patients taking purine analogues weremore likely than 5-ASA patients to discontinue therapy due to adverse events. No firm conclusions
can be drawn from the two small studies that compared azathioprine to infliximab or adalimumab. Adalimumab may be superior to
azathioprine but further research is needed to confirm these results. Further research investigating the efficacy and safety of azathioprine
and 6-mercaptopurine in comparison to other active medications in patients with surgically-induced remission of CD is warranted.
P L A I N L A N G U A G E S U M M A R Y
Azathioprine and 6-mercaptopurine for the maintenance of surgically-induced remission in Crohn’s disease
Prevention of clinical relapse (resumption of symptoms of active disease) and endoscopic relapse (signs of mucosal inflammation upon
examination with an endoscope) are key objectives in the management of Crohn’s disease. There is no treatment currently available that
completely prevents relapse and is without significant side-effects. The purpose of this systematic review was to examine the effectiveness
and side effects of purine analogue medications (azathioprine and 6-mercaptopurine) used to prevent relapse in Crohn’s patients in
surgically-induced remission
This review identified seven studies that included a total of 584 participants. One study compared azathioprine to placebo (e.g. a sugar
pill). Another study compared 6-mercaptopurine to 5-aminosalicylic acid (5-ASA) or placebo. Three studies compared azathioprine
to 5-ASA drugs. One small study compared azathioprine to both 5-ASA and adalimumab (a biological drug that is a tumour necrosis
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factor-alpha antagonist). One small study compared azathioprine to infliximab (a biological drug that is a tumour necrosis factor-alpha
antagonist). The study that compared azathioprine to infliximab (22 patients) found that the effects on the proportion of patients who
had a clinical or endoscopic relapse were uncertain. A small study (33 patients) found reduced clinical and endoscopic relapse rates
favouring adalimumab over azathioprine. No firm conclusions can be drawn from the two small studies that compared azathioprine
to infliximab or adalimumab. Adalimumab may be superior to azathioprine but further research is needed to confirm these results.
A pooled analysis of two studies (168 patients) suggests that purine analogues may be superior to placebo for preventing clinical
relapse in Crohn’s patients in surgically-induced remission. One study (87 patients) found a reduction in endoscopic relapse rates
favouring 6-mercaptopurine over placebo. A pooled analysis of five studies (425 patients) found no difference in clinical relapse rates
between purine analogues and 5-ASA agents. One study (35 patients) found no difference in endoscopic relapse at 12 months between
azathioprine and 5-ASA. Another study (91 patients) found reduced endoscopic relapse rates at 24 months favouring 6-mercaptopurine
over 5-ASA patients. Patients taking purine analogues were more likely than 5-ASA patients to discontinue therapy due to side effects.
Commonly reported side effects across the studies included leucopenia (a decrease in the number of white blood cells), arthralgia
(joint pain), abdominal pain or severe epigastric intolerance, elevated liver enzymes, nausea and vomiting, pancreatitis (inflammation
of the pancreas), anaemia (a decrease in the number of red blood cells), exacerbation (worsening) of Crohn’s disease, nasopharyngitis
(common cold), and flatulence. The results of this review need to be interpreted with caution as they are based on small numbers of
patients and the overall quality of the evidence from the studies was rated as low or very low due to lack of precision of the results,
inconsistent results across studies and the low methodological quality of some studies. Further research investigating the effectiveness
and side effects of azathioprine and 6-mercaptopurine in comparison to other medications in patients with surgically-induced remission
of Crohn’s disease is warranted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Azathioprine (AZA) or 6-mercaptopurine (6-MP) versus placebo for maintenance of surgically-induced remission in Crohn’s disease
Patient or population: Patients in remission after surgery for Crohn’s disease
Settings: Outpatient
Intervention: AZA or 6-MP versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control AZA or 6-MP versus
placebo
Clinical relapse 630 per 10001 466 per 1000
(365 to 592)
RR 0.74
(0.58 to 0.94)
168
(2 studies)
⊕⊕©©
low2,3
Endoscopic relapse (6-
MP study)
425 per 10001 170 per 1000
(81 to 353)
RR 0.40
(0.19 to 0.83)
87
(1 study)
⊕⊕©©
low4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimates come from control arm of meta-analysis, based on included trials.
2 Sparse data (93 events).
3 High risk of bias in one study in pooled analysis due to single-blind design.
4 Very sparse data (25 events).
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B A C K G R O U N D
Description of the condition
Crohn’s disease (CD) is a chronic inflammatory disorder that can
involve any part of the gastrointestinal tract. There is no cure
for the disease, and management strategies are mainly focused
on induction and maintenance of remission. Approximately 75%
of patients with CD will eventually undergo surgical resection (
Bernell 2000), and this can induce remission.However endoscopic
recurrence of disease has been reported to be as high as 73% at one
year post surgery (Rutgeerts 1990), and clinical relapse rates have
been reported to range from 22 to 55% at five years post surgery
(Williams 1990). There is no standard therapy for the prevention
of postoperative recurrence in CD (Hanauer 2001). A number of
agents have been studied, but considerable uncertainty remains as
to the efficacy of such treatments.
Description of the intervention
Corticosteroids, the mainstay of treatment of acute exacerbations,
are not effective for maintenance of remission in CD (Steinhart
2003), and chronic use is limited by numerous adverse events. 5-
Aminosalicylic acid agents have been shown to be safe and may
be effective for maintenance of post-surgical remission, although
the existing data suggests that the efficacy of these agents may be
limited (Gordon 2011). Probiotics and budesonide do not appear
to provide any benefit for maintenance of surgically-induced re-
mission (Rolfe 2006; Benchimol 2009; Doherty 2009). Nitroim-
idazole antibiotics may reduce the risk of relapse in surgically-in-
duced remission (Doherty 2009). However these agents are not
well tolerated and are associated with a higher risk of serious ad-
verse events (Doherty 2009). TNF-alpha antagonists may provide
a benefit in post-operative Crohn’s disease but these agents are ex-
pensive. One small study suggests that infliximab may provide a
benefit for reducing the risk of relapse in surgically-induced re-
mission (Regueiro 2009). Another small study suggests that adal-
imumab my be superior to azathioprine for reducing the risk of
relapse in post-operative CD patients (Savarino 2013). Further re-
search is needed to confirm these benefits, Purine analogues such
as azathioprine and 6-mercaptopurine have been extensively used
for maintenance of remission in both Crohn’s disease and ulcera-
tive colitis and are relatively inexpensive.
How the intervention might work
Azathioprine is a prodrug which is non-enzymatically degraded to
6-mercaptopurine which in turn is metabolised to the active com-
ponent, 6-thioguanine nucleotide (6-TGN). 6-TGN is thought
to work by inhibiting the proliferation of T and B lymphocytes
and reducing the numbers of cytotoxic T cells and plasma cells.
There are some trial data which suggest that neutrophil count is
a predictor of induction and maintenance of remission (Colonna
1994), which may suggest the mechanism of action, although this
is not well understood. Themajor limiting factor for long term use
has been the occurrence of adverse events in approximately 10% of
patients leading to withdrawal of therapy (Hafraoui 2002), with
dose-dependent and idiosyncratic adverse events occurring.
Why it is important to do this review
Relatively few studies have been published that investigate the
role of azathioprine or 6-mercaptopurine for maintenance of re-
mission following surgery in patients with CD. One multicentre
randomised placebo controlled trial involving 81 patients found
a significant reduction in endoscopic recurrence when azathio-
prine was used in conjunction with metronidazole in comparison
to metronidazole alone (D’Haens 2008). In another multicentre
randomised controlled trial, it was concluded that 6-mercaptop-
urine was more effective than either mesalamine or placebo at pre-
venting postoperative recurrence at 24 months following surgery
(Hanauer 2001). However, a single-center randomised open-la-
bel trial found no significant difference in clinical relapse rates be-
tween azathioprine and mesalamine (Ardizzone 2004). An up-to-
date systematic review using the Cochrane Collaboration format is
indicated to summarise the current evidence on the use of purine
analogues for the maintenance of surgically induced remission in
CD.
O B J E C T I V E S
The primary objective was to evaluate the efficacy and safety of
azathioprine and 6-mercaptopurine for maintenance of surgically-
induced remission in CD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials were considered for inclusion.
Types of participants
Patients of any age with CD who were in remission following
surgery, defined by a recognized CD activity index or endoscopy,
or who had undergone a curative surgical resection, as defined by
the authors of the primary studies were considered for inclusion.
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Types of interventions
Trials which compared azathioprine or 6-mercaptopurine to
placebo or another active intervention with treatment durations
of at least six months were considered for inclusion.
Types of outcome measures
Primary outcomes
The primary outcome measure was clinical relapse or endoscopic
relapse as defined by the primary studies.
Secondary outcomes
Secondary outcomes included the incidence of adverse events,
withdrawal due to adverse events, and serious adverse events. Ad-
verse events that are known to be associated with azathioprine or
6-mercaptopurine were reported. These adverse events could in-
clude:
a. Bone marrow suppression: pancytopenia, leucopenia, neutrope-
nia, thrombocytopenia;
b. Hypersensitive reactions: malaise, vomiting, diarrhoea, rash,
hypotension;
c. Malignancy
d. Liver function impairment, jaundice;
e. Pancreatitis;
f. Pulmonary: pneumonitis; and
g. Renal: interstitial nephritis.
Search methods for identification of studies
Electronic searches
A. Electronic searching
The following electronic databases were searched for relevant stud-
ies:
1. PubMed (from inception to April 30, 2014);
2. MEDLINE (from inception to April 30, 2014);
3. EMBASE (from inception to April 30, 2014);
4. Cochrane Central Register of Controlled Trials (CENTRAL,
on 30 April 2014); and
5. Cochrane Inflammatory Bowel Disease and Functional Bowel
Disortders Group Specialized Trials Register.
The search strategy was not limited by language. The search strat-
egy used for each database is reported in Appendix 1. There is
some evidence that data from abstracts can be inconsistent with
data in published articles (Pitkin 1999). Thus studies that were
reported in abstract form only were not included in this review.
Searching other resources
B. Reference searching
The references of all identified studies were inspected for more
trials.
C. Personal contacts
Leaders in the field were contacted to try to identify other studies.
D. Drug companies
The manufacturers of azathioprine and 6-mercaptopurine were
contacted for any additional data.
Data collection and analysis
All identified abstracts and results from searches were reviewed by
two authors (MG and KV). If the reference appeared relevant, a
full copy of the study was obtained.
Selection of studies
Two authors (MG and KV), after reading the full texts, indepen-
dently assessed the eligibility of all trials identified based on the in-
clusion criteria above. Disagreement among authors was discussed
and agreement reached by consensus.
Data extraction and management
A data extraction form was developed to extract information on
relevant features and results of included studies. Two authors (MG
and KV) independently extracted and recorded data on the pre-
defined checklist. Extracted data included the following items:
a. characteristics of patients: age, sex, disease distribution, disease
duration, disease activity index;
b. total number of patients originally assigned to each treatment
group;
c. intervention: dose of azathioprine or 6-mercaptopurine;
d. control: placebo, other drugs;
e. concurrent medications; and
f. outcomes: time of assessment, length of follow up, type of
Crohn’s disease activity index used, definitions of remission and
relapse, relapse rates, adverse events.
Assessment of risk of bias in included studies
The methodological quality of selected trials was assessed inde-
pendently by two authors (MG and KV) using the Cochrane risk
of bias tool (Higgins 2011).
Factors assessed included:
1. sequence generation (i.e. was the allocation sequence adequately
generated?);
2. allocation sequence concealment (i.e. was allocation adequately
concealed?);
3. blinding (i.e. was knowledge of the allocated intervention ade-
quately prevented during the study?);
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4. incomplete outcome data (i.e. were incomplete outcome data
adequately addressed?);
5. selective outcome reporting (i.e. are reports of the study free of
suggestion of selective outcome reporting?);
6. other potential sources of bias (i.e. was the study apparently free
of other problems that could put it at a high risk of bias?).
A judgement of ’Yes’ indicates low risk of bias, ’No’ indicates high
risk of bias, and ’Unclear’ indicates unclear or unknown risk of bias.
Disagreements were resolved by consensus. Study authors were
contacted for further information when insufficient information
was provided to determine the risk of bias.
The overall quality of evidence was assessed using the GRADE
approach (Guyatt 2008; Schünemann 2011). The GRADE ap-
proach appraises the quality of a body of evidence based on the
extent to which one can be confident that an estimate of effect
or association reflects the item being assessed. Randomised trials
start as high quality evidence, but may be downgraded due to: risk
of bias (methodological quality), indirectness of evidence, unex-
plained heterogeneity, imprecision (sparse data) and publication
bias. The overall quality of the evidence for each outcome was
determined after considering each of these factors and graded as:
• High: further research is very unlikely to change confidence
in the estimate of effect;
• Moderate: further research is likely to have an important
impact on confidence in the estimate of effect and may change
the estimate;
• Low: further research is very likely to have an important
impact on confidence in the estimate of effect and is likely to
change the estimate; and
• Very low: any estimate of effect is very uncertain.
Measures of treatment effect
The Cochrane Collaboration review manager (RevMan) software
(version 5.3) was used for data analysis (RevMan 2014). We cal-
culated the risk ratio and corresponding 95% confidence interval
(95%CI) for dichotomous outcomes.We planned to calculate the
mean difference (MD) and corresponding 95%CI for continuous
outcomes measured using the same units. We planned to calculate
the standardized mean difference (SMD) and corresponding 95%
CI for continuous outcomes where different scales were used to
evaluate the same outcome.
Unit of analysis issues
When cross-over trials were included, data from the first phase
of the study were extracted for analysis (i.e. before the cross-
over occurred). Separate analyses were conducted for comparisons
between azathioprine or 6-mercaptopurine versus placebo, and
azathioprine or 6-mercaptopurine versus active comparator (e.g.
mesalamine). If studies randomised subjects to more than one aza-
thioprine or 6-mercaptopurine treatment arm, these were com-
bined for the primary analysis. Although some studies reported
more than one efficacy or safety event per subject, the primary
analysis considered only the proportion of subjects who experi-
enced at least one event.
Dealing with missing data
Data were analysed according to the intention-to-treat principle.
Patients with final missing outcomes were assumed to have re-
lapsed.
Assessment of heterogeneity
Heterogeneity among trial results was assessed by visual inspection
of forest plots andby calculating theChi2 test (a P value of 0.10was
regarded as statistically significant heterogeneity).We also used the
I2 statistic to quantity the effect of heterogeneity (Higgins 2003).
A random-effects model was used in situations of unexplained
heterogeneity. We conducted sensitivity analyses as appropriate to
investigate heterogeneity. For example, if a pooled analysis showed
statistically significant heterogeneity and a visual inspection of the
forest plot identified studies that may have contributed to this
heterogeneity the analysis was repeated excluding these studies to
see if this explained the heterogeneity.
Assessment of reporting biases
We planned to investigate the possibility of a publication bias
through the construction of funnel plots (trial effects versus trial
size), although this was not completed as the number of studies
was small.
Data synthesis
Data from individual trials were combined for meta-analysis if the
interventions, patient groups and outcomes were sufficiently sim-
ilar (determined by consensus). We calculated the pooled RR and
corresponding 95% CI for dichotomous outcomes. Meta-analy-
sis was carried out using a fixed-effect model. A random-effects
model was used in situations of statistically significant heterogene-
ity. Data were not to be pooled for meta-analysis if a high degree
of heterogeneity was detected (i.e. I2 > 75%).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were planned to further study the effects of a
number of variables on the outcomes, when appropriate data were
available. However there were not sufficient studies to carry out
such analyses. Planned subgroup analyses included:
a. Length of follow up; and
b. Drug type (i.e. azathioprine or 6-mercaptopurine).
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Sensitivity analysis
Sensitivity analyses based on random-effects versus fixed-effect
models were plannedwhere appropriate data or numbers of studies
were available. Sensitivity analysis was also undertaken to explore
possible explanations for significant heterogeneity.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of ex-
cluded studies.
The electronic database search on 30 April 2014 identified 745
studies. After removal of duplicates, 635 studies were screened
for inclusion. Of these, 24 studies were judged to be potentially
relevant and subjected to full text review (See Figure 1). Experts
were contacted, but no responses were received and no further
studies were identified from drug companies.
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Figure 1. Study flow diagram.
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Four reports of three studies were excluded for failing to meet
the inclusion criteria. One study was excluded because it was not
a randomised controlled trial as confirmed by the author (Nos
2000). The other two studies were excluded because all patients
received azathioprine as part of their post-surgical maintenance
therapy (Mañosa 2013; Ferrante 2014).
Twenty reports of seven studies satisfied the inclusion criteria and
were included in the review. Three studies compared azathio-
prine to 5-aminosalicylic acid (Ardizzone 2004; Herfarth 2006;
Reinisch 2010).D’Haens 2008 compared azathioprine to placebo.
All patients in this study were taking concurrent metronidazole or
ornidazole. Hanauer 2004 compared 6-mercaptopurine to both
5-aminosalicylic acid and placebo. Savarino 2013 compared aza-
thioprine to both 5-aminosalicylic acid and adalimumab. Armuzzi
2013 was a randomised open-label pilot study that compared aza-
thioprine to infliximab. All patients in this study took oralmetron-
idazole for two weeks post-surgery. There were no cross-over trials.
The total number of participants in the seven studies was 584. All
participants were adult patients with Crohn’s disease, the majority
of whom were recruited within two weeks of surgery or before
hospital discharge after remission-inducing surgery. The 78 par-
ticipants in one study were enrolled between 6 and 24 months
postoperatively and were in clinical remission but had endoscopic
recurrence as an inclusion criterion (Reinisch 2010).
Risk of bias in included studies
A summary of the risk of bias analysis is shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Six studies were rated as low risk for random sequence generation
(selection bias) because these studies employed computer-gener-
ated randomisation (Ardizzone 2004; Hanauer 2004; Herfarth
2006; D’Haens 2008; Reinisch 2010; Savarino 2013). Armuzzi
2013 was rated as unclear risk of bias for random sequence gen-
eration because the method of randomisation was not described
in the manuscript. Four studies were rated as low risk of bias for
allocation concealment (selection bias) (Hanauer 2004; Herfarth
2006; D’Haens 2008; Savarino 2013). Three studies were rated
as unclear risk of bias for allocation concealment as the methods
were not clearly described in the manuscripts (Ardizzone 2004;
Reinisch 2010; Armuzzi 2013). The authors were contacted, but
no further information was given.
Three studies were double-blinded and were judged to be at low
risk of bias for blinding of participants and personnel (perfor-
mance bias) (Hanauer 2004; Herfarth 2006; Reinisch 2010). The
D’Haens 2008 study was investigator-blinded and was judged to
be at high risk of bias for blinding of participants. Three studies
were open-label and were judged to be at high risk of bias for
blinding of participants and personnel (Ardizzone 2004; Armuzzi
2013; Savarino 2013).
Six studies reported full and appropriate data and satisfactorily
documented withdrawals and dropouts and were therefore judged
to be at low risk of bias for incomplete outcome data (attrition bias)
and selective reporting (reporting bias) (Hanauer 2004; Herfarth
2006; D’Haens 2008; Reinisch 2010; Armuzzi 2013; Savarino
2013). Ardizzone 2004 was judged to be at unclear risk of bias
for incomplete outcome data and selective reporting owing to
inadequately described outcomes and potentially selective data
reporting.
All seven studies were judged to be a low risk of bias for other
sources of bias. Reinisch 2010 was funded by a drug company with
some of the authors employed by the drug company although the
extent of their involvement was unclear.
Effects of interventions
See: Summary of findings for the main comparison
Azathioprine or 6-mercaptopurine versus placebo formaintenance
of surgically-induced remission in Crohn’s disease; Summary
of findings 2 Azathioprine or 6-mercaptopurine versus 5-
aminosalicylic acid for maintenance of surgically-induced
remission in Crohn’s disease; Summary of findings 3
Azathioprine versus infliximab for maintenance of surgically-
induced remission in Crohn’s disease; Summary of findings 4
Azathioprine versus adalimumab for maintenance of surgically-
induced remission in Crohn’s disease
Azathioprine or 6-mercaptopurine versus placebo
Two studies with a total of 168 participants compared azathio-
prine or 6-mercaptopurine to placebo (Hanauer 2004; D’Haens
2008). In one of these studies all patients were also taking either
metronidazole or ornidazole (D’Haens 2008).
Efficacy
Meta-analysis of two studies with 168 participants comparing aza-
thioprine or 6-mercaptopurine to placebo, showed a statistically
significant difference in clinical relapse rates favouring purine ana-
logues. Forty-eight per cent of patients in the purine analogue
group experienced a clinical relapse compared to 63% of placebo
patients (RR 0.74, 95% CI 0.58 to 0.94; See Figure 3). No het-
erogeneity was detected for this comparison (P = 0.53, I2 = 0%).
However, there was clinical and methodological heterogeneity be-
tween these two studies, regarding the choice of purine analogue
and the use of other medications. A GRADE analysis indicated
that the overall quality of the evidence for this outcome was low
due to high risk of bias (one study in the pooled analysis was single
blind) and sparse data (93 events, See Summary of findings for
the main comparison). A sensitivity analysis using a random-ef-
fects model showed a statistically significant difference in clinical
relapse rates favouring purine analogues (RR 0.76, 95% CI 0.61
to 0.95).
Figure 3. Forest plot of comparison: 2 AZA or 6MP versus placebo, outcome: 2.1 Clinical relapse (fixed-
effect).
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One study reported on endoscopic relapse at two years as an out-
come (Hanauer 2004). There was a statistically significant differ-
ence in endoscopic relapse rates favouring 6-mercaptopurine. Sev-
enteen per cent of patients in the 6-mercaptopurine group had an
endoscopic relapse at two years compared to 42% of placebo pa-
tients (RR 0.40, 95% CI 0.19 to 0.83). A GRADE analysis indi-
cated that the overall quality of the evidence for this outcome was
low due to very sparse data (25 events, See Summary of findings
for the main comparison).
Safety
Both studies reported on the proportion of patients who withdrew
due to an adverse event. Adverse events leading to withdrawal were
not significantly more common in the azathioprine or 6-mercap-
tupurine groups. Fifteen per cent of patients in the purine ana-
logue group withdrew due to adverse events compared to 11% of
placebo patients (RR 1.33, 95% CI 0.59 to 2.98). No heterogene-
ity was detected for this comparison (P = 0.32, I2 = 1%).
Common adverse events reported in the study that compared aza-
thioprine to placebo included metallic taste, headache, paraesthe-
sias, epigastric pain, nausea, arthralgia, angina, skin rash, and el-
evated liver enzymes (D’Haens 2008). Common adverse events
reported in the study that compared 6-mercaptopurine to placebo
included leukopenia, alopecia, diarrhoea, flatus, gastrointesti-
nal bleeding, phlebitis, abdominal pain, and headache (Hanauer
2004).
Azathioprine or 6-mercaptopurine versus 5-aminosalicylic
acid
Five studies involving 425 participants compared either azathio-
prine or 6-mercaptopurine to 5-aminosalicylic acid (Ardizzone
2004; Hanauer 2004; Herfarth 2006; Reinisch 2010; Savarino
2013). Reinisch 2010 enrolled patients who were in clinical re-
mission but had endoscopic recurrence as an inclusion criteria.
Efficacy
Five studies involving 425 patients reported on clinical relapse at
one or two years as an outcome (Ardizzone 2004; Hanauer 2004;
Herfarth 2006; Reinisch 2010; Savarino 2013). The pooled anal-
ysis showed no statistically significant difference in clinical relapse
rates betweenpurine analogues and5-aminosalicylates. Sixty-three
per cent (137/218) of patients in the purine analogues group ex-
perienced a clinical relapse compared to 54% (112/207) of pa-
tients in the 5-aminosalicylates group (RR 1.15, 95% CI 0.99
to 1.34; See Figure 4). Statistical heterogeneity was moderate (I
2= 45%). A GRADE analysis indicated that the overall quality of
the evidence for the primary outcome (clinical relapse) was very
low due to high risk of bias (two studies in the pooled analysis
were not blinded), moderate heterogeneity and sparse data (249
events, see Summary of findings 2). A sensitivity analysis using
a random-effects model showed no statistically significant differ-
ence in clinical relapse rates between the two groups (RR 1.14,
95% CI 0.93 to 1.41; see Analysis 2.2). A sensitivity analysis ex-
cluding the study that included patients with endoscopic recur-
rence (Reinisch 2010), showed no statistically significant differ-
ence in rates of clinical relapse (RR 1.06, 95% CI 0.91 to 1.24; see
Analysis 2.3). However, there was far less statistical heterogeneity
for this comparison (P = 0.36, I2 = 6%) which suggests that the
heterogeneity can be explained by the inclusion of the study that
enrolled patients with endoscopic recurrence. A GRADE analysis
indicated that the overall quality of the evidence for this outcome
was low due to high risk of bias (two studies in the pooled analysis
were not blinded) and sparse data (214 events, See Summary of
findings 2).
Figure 4. Forest plot of comparison: 1 AZA/6MP vs 5-ASA, outcome: 1.1 Clinical relapse (fixed-effect).
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A subgroup analysis by drug type suggests a statistically signifi-
cant benefit for 5-aminosalicylates over azathioprine but no sta-
tistically significant difference for 5-aminosalicylates over 6-mer-
captopurine. Sixty-eight per cent of 6-mercaptopurine patients
had a clinical relapse compared to 75% of 5-aminosalicylate pa-
tients (RR 0.91, 95% CI 0.70 to 1.18; 91 patients 1 study). Sixty-
one per cent of azathioprine patients experienced a clinical relapse
compared to 48% of 5-aminosalicylate patients (RR 1.25, 95%
CI 1.04 to 1.51; 4 studies, 334 patients). There was no significant
statistical heterogeneity (P = 0.28, I2= 22%) for this comparison.
A GRADE analysis indicated that the overall quality of the evi-
dence for this outcome was low due to high risk of bias (two stud-
ies in the pooled analysis were not blinded) and sparse data (184
events, See Summary of findings 2). A sensitivity analysis exclud-
ing the study that included patients with endoscopic recurrence
(Reinisch 2010), showed no statistically significant difference in
clinical relapse rates (RR 1.13, 95% CI 0.93 to 1.38; 3 studies,
256 patients).
A subgroup analysis by length of follow-up suggests a statistically
significant benefit for 5-aminosalicylates over antimetabolites at
12 months but not at 24 months. Seventy-six per cent of patients
in the antimetabolite group experienced a clinical relapse at 12
months compared to 54% of 5-aminosalicylate patients (RR 1.40,
95%CI1.12 to 1.74; 2 studies, 157 patients). A high degree of het-
erogeneity was detected for this comparison (P = 0.04, I2 = 77%).
At 24 months, 55% of patients in the antimetabolite group expe-
rienced a clinical relapse compared to 54% of 5-aminosalicylate
patients (RR 1.01, 95% CI 0.81 to 1.24; 3 studies, 268 patients).
No heterogeneity was detected for this comparison (P = 0.51, I
2 = 0%). A sensitivity analysis excluding the study that included
patients with endoscopic recurrence (Reinisch 2010), showed no
statistically significant difference in rates of clinical relapse at one
year (RR 1.18, 95% CI 0.98 to 1.43).
Two studies reported on endoscopic relapse at one or two years
as an outcome (Hanauer 2004; Savarino 2013). These studies
were not pooled for analysis due to a high degree of heterogene-
ity. There was no statistically significant difference in endoscopic
relapse at 12 months between azathioprine and 5-aminosalicylate
patients. Sixty-five per cent of azathioprine patients had an en-
doscopic relapse compared to 83% of 5-aminosalicylate patients
(RR 0.78, 95% CI 0.52 to 1.17). A GRADE analysis indicated
that the overall quality of the evidence for this outcome was very
low due to high risk of bias (the study was not blinded) and very
sparse data (26 events, See Summary of findings 2). There was a
statistically significant difference in the rate of endoscopic relapse
at 24 months between 6-mercaptopurine and 5-aminosalicylate
patients. Seventeen per cent of 6-mercaptopurine patients had an
endoscopic relapse compared to 48%of 5-aminosalicylate patients
(RR 0.36, 95% CI 0.18 to 0.72). A GRADE analysis indicated
that the overall quality of the evidence for this outcome was low
due to very sparse data (29 events, See Summary of findings 2).
Safety
Four studies involving 334 patients reported on the proportion
of patients who had at least one adverse event (Ardizzone 2004;
Herfarth 2006; Reinisch 2010; Savarino 2013). The pooled anal-
ysis showed no statistically significant difference in the proportion
of patients who experienced an adverse event. Sixty-two per cent
(106/171) of patients in the azathioprine group experienced an
adverse event compared to 56% (92/163) of patients in the 5-
aminosalicylates group (RR 1.08, 95% CI 0.93 to 1.27). No sig-
nificant heterogeneity was found for this comparison (P = 0.20, I
2 = 36%).
Five studies involving 423 patients reported on the proportion of
patients who withdrew due to an adverse event (Ardizzone 2004;
Hanauer 2004; Herfarth 2006; Reinisch 2010; Savarino 2013).
Adverse events that required withdrawal were significantly more
common in the purine analogue group compared to the 5-aminos-
alicylic acid group. Twenty per cent of patients in the purine ana-
logue group withdrew due to an adverse event compared to 10%
of 5-aminosalicylate patients (RR 2.07, 95% CI 1.26 to 3.39).
No heterogeneity was detected for this comparison (P = 0.53, I2
= 0%). A subgroup analysis by drug type suggests a significantly
higher risk of withdrawal due to adverse events for patients receiv-
ing azathioprine but not for 6-mercaptopurine. Twenty per cent
of patients in the azathioprine group withdrew due to an adverse
event compared to 9% of 5-aminosalicylate patients (RR 2.35,
95% CI 1.31 to 4.22; 4 studies, 332 patients). No heterogeneity
was detected for this comparison (P = 0.47, I2 = 0%).
Nineteen per cent of 6-mercaptopurine patients withdrew due to
an adverse event compared to 14% of 5-aminosalicylate patients
(RR 1.40, 95% 0.54 to 3.62). Two studies involving 169 patients
reported on the proportion of patients who had a serious adverse
event (Hanauer 2004;Reinisch 2010). The pooled analysis showed
no statistically significant difference in the proportion of patients
who experienced a serious adverse event. Elevenper cent (10/88) of
patients in the antimetabolite group experienced an adverse event
compared to 1% (1/81) of patients in the 5-aminosalicylates group
(RR 2.61, 95%CI 0.04 to 162.02). A high degree of heterogeneity
was detected for this comparison (P = 0.05, I2 = 74%).
Commonly reported adverse events included leucopenia (
Ardizzone 2004; Hanauer 2004; Herfarth 2006; Reinisch 2010),
arthralgia (Hanauer 2004; Herfarth 2006; Reinisch 2010;
Savarino 2013), abdominal pain or severe epigastric intolerance
(Ardizzone 2004; Herfarth 2006; Reinisch 2010; Savarino 2013),
elevated liver enzymes (Ardizzone 2004; Hanauer 2004; Herfarth
2006), nausea and vomiting (Herfarth 2006; Reinisch 2010;
Savarino 2013), pancreatitis (Ardizzone 2004; Herfarth 2006;
Reinisch 2010), anaemia (Herfarth 2006; Reinisch 2010), ex-
acerbation of Crohn’s disease (Reinisch 2010; Savarino 2013),
nasopharyngitis (Reinisch 2010; Savarino 2013), and flatulence
(Hanauer 2004; Reinisch 2010).
14Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Azathioprine versus infliximab
Efficacy
One studywith a total of 22 participants compared azathioprine to
infliximab (Armuzzi 2013). There was no statistically significant
difference in the proportion of patients who had a clinical relapse.
Eighteen per cent (2/11) of patients in the azathioprine group
relapsed clinically compared to 9% (1/11) of infliximab patients
(RR 2.00, 95% CI 0.21 to 18.98). A GRADE analysis indicated
that the overall quality of the evidence for this outcome was very
low due to high risk of bias (the study was not blinded) and very
sparse data (3 events, See Summary of findings 3). There was no
statistically significant difference in the proportion of patients who
had endoscopic relapse. Forty per cent (4/10) of patients in the
azathioprine group relapsed endoscopically compared to 9% (1/
11) of infliximab patients (RR 4.40, 95% CI 0.59 to 33.07). A
GRADE analysis indicated that the overall quality of the evidence
for this outcome was very low due to high risk of bias (the study
was not blinded) and very sparse data (5 events, See Summary of
findings 3).
Safety
There was no statistically significant difference in the proportion
of patients who withdrew due to adverse events. One patient in
the azathioprine group (1/11, 9%) withdrew due to an adverse
event (i.e. nausea and epigastric pain) compared to no patients in
the infliximab group (RR 3.00, 95% CI 0.14 to 66.53). No other
adverse events were reported.
Azathioprine versus adalimumab
Efficacy
One study with a total of 33 participants compared azathioprine
to adalimumab (Savarino 2013). There was a statistically signif-
icant difference in the proportion of patients who had a clinical
relapse. Sixty-five per cent (11/17) of patients in the azathioprine
group relapsed clinically compared to 12% (2/16) of adalimumab
patients (RR 5.18, 95% CI 1.35 to 19.83). A GRADE analy-
sis indicated that the overall quality of the evidence for this out-
come was very low due to high risk of bias (the study was not
blinded) and very sparse data (13 events, See Summary of findings
4). There was a statistically significant difference in the proportion
of patients who had endoscopic relapse. Sixty-five per cent (11/
17) of patients in the azathioprine group relapsed endoscopically
compared to 6% (1/16) of adalimumab patients (RR 10.35, 95%
CI 1.50 to 71.32). A GRADE analysis indicated that the overall
quality of the evidence for this outcome was very low due to high
risk of bias (the study was not blinded) and very sparse data (12
events, See Summary of findings 4).
Safety
Savarino 2013 reported on the proportion of patients who experi-
enced at least one adverse event and on the proportion of patients
who withdrew due to adverse events. There was no statistically
significant difference in the proportion of patients who had an
adverse event. Eight-eight per cent (15/17) had an adverse event
compared to 69% (11/16) of adalimumab patients (RR 1.28, 95%
CI 0.88 to 1.86). There was no statistically significant difference
in the proportion of patients who withdrew due to adverse events.
Twelve per cent (2/17) of azathioprine patients withdrew due to
an adverse event compared to 6% (1/16) of patients in the adal-
imumab group (RR 1.88, 95% CI 0.19 to 18.80). Commonly
reported adverse events included bronchitis, nasopharyngitis, flu,
abdominal pain, nausea and vomiting, arthralgia, dermatitis, and
abscess (Savarino 2013).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Azathioprine (AZA) or 6-mercaptopurine (6-MP) versus 5-aminosalicylic acid (5-ASA) for maintenance of surgically-induced remission in Crohn’s disease
Patient or population: Patients in remission after surgery for Crohn’s disease
Settings: Outpatient
Intervention: AZA or 6-MP versus 5-ASA
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control AZA or 6-MP versus 5-
ASA
Clinical relapse 541 per 10001 622 per 1000
(536 to 725)
RR 1.15
(0.99 to 1.34)
425
(5 studies)
⊕©©©
very low2,3,4
Clinical relapse (sensi-
tivity analysis excluding
study that enrolled pa-
tients with endoscopic
recurrence)
594 per 10001 630 per 1000
(540 to 737)
RR 1.06
(0.91 to 1.24)
347
(4 studies)
⊕⊕©©
low2,5
Clinical relapse (sub-
group analysis - AZA
studies only)
485 per 10001 606 per 1000
(504 to 732)
RR 1.25
(1.04 to 1.51)
334
(4 studies)
⊕⊕©©
low2,6
Endoscopic relapse
(AZA study)
833 per 10001 650 per 1000
(433 to 975)
RR 0.78
(0.52 to 1.17)
35
(1 study)
⊕©©©
very low7,8
Endoscopic relapse (6-
MP study)
477 per 10001 172 per 1000
(86 to 343)
RR 0.36
(0.18 to 0.72)
91
(1 study)
⊕⊕©©
low9
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio16
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimates come from control arm of meta-analysis, based on included trials.
2 High risk of bias in two studies in pooled analysis due to lack of blinding.
3 Sparse data (249 events).
4 Moderate heterogeneity I2 = 45%.
5 Sparse data (214 events).
6 Sparse data (184 events).
7 High risk of bias due to lack of blinding.
8 Very sparse data (26 events) and wide confidence interval.
9 Very sparse data (29 events) and wide confidence interval.
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Azathioprine (AZA) versus infliximab for maintenance of surgically-induced remission in Crohn’s disease
Patient or population: Patients in remission after surgery for Crohn’s disease
Settings: Outpatient
Intervention: AZA versus infliximab
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control AZA versus infliximab
Clinical relapse 91 per 10001 182 per 1000
(19 to 1727)
RR 2.00
(0.21 to 18.98)
22
(1 study)
⊕©©©
very low2,3
Endoscopic relapse 91 per 10001 400 per 1000
(54 to 3009)
RR 4.40
(0.59 to 33.07)
21
(1 study)
⊕©©©
very low2,4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimates come from control arm of meta-analysis, based on included trial.
2 High risk of bias due to lack of blinding.
3 Very sparse data (3 events) and very wide confidence interval.
4 Very sparse data (5 events) and very wide confidence interval.
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Azathioprine (AZA) versus adalimumab for maintenance of surgically-induced remission in Crohn’s disease
Patient or population: Patients in remission after surgery for Crohn’s disease
Settings: Outpatient
Intervention: AZA versus adalimumab
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control AZA versus adalimumab
Clinical relapse 125 per 10001 648 per 1000
(169 to 2479)
RR 5.18
(1.35 to 19.83)
33
(1 study)
⊕©©©
very low2,3
Endoscopic relapse (6-
MP study)
62 per 10001 642 per 1000
(93 to 4422)
RR 10.35
(1.50 to 71.32)
33
(1 study)
⊕©©©
very low2,4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimates come from control arm of meta-analysis, based on included trial.
2 High risk of bias due to lack of blinding.
3 Very sparse data (13 events) and very wide confidence interval.
4 Very sparse data (12 events) and very wide confidence interval.
1
9
A
z
a
th
io
p
rin
e
a
n
d
6
-m
e
rc
a
p
to
p
u
rin
e
fo
r
m
a
in
te
n
a
n
c
e
o
f
su
rg
ic
a
lly
-in
d
u
c
e
d
re
m
issio
n
in
C
ro
h
n
’s
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
The Hanauer 2004 and D’Haens 2008 studies compared azathio-
prine or 6-mercaptopurine to placebo, with meta-analysis suggest-
ing the superiority of purine analogues over placebo for preventing
clinical (2 studies, 168 patients) and endoscopic relapse (1 study,
87 patients). This small evidence base gives some support for the
use of purine analogues for maintenance of surgically-induced re-
mission in CD.
However, meta-analysis of five studies (n = 425 patients) compar-
ing purine analogues to 5-aminosalicylic acid found no statistically
significant differences in clinical relapse rates (Ardizzone 2004;
Hanauer 2004; Herfarth 2006; Reinisch 2010; Savarino 2013). A
subgroup analysis by drug type suggests that azathioprine may be
significantly inferior to 5-aminosalicylic acid. Sixty-one per cent
of azathioprine patients had a clinical relapse compared to 48% of
5-aminosalicylic acid patients (RR 1.25, 95% CI 1.04 to 1.51).
There was no statistically significant difference in clinical relapse
rates between 6-mercaptopurine and 5-aminosalicylic acid. How-
ever, clinical heterogeneity among the pooled studies was a con-
cern. Reinisch 2010 enrolled patients with active endoscopic re-
currence within 6 to 24 months of surgery, whereas the patients in
the other three studies were enrolled within two weeks of surgery
and were unlikely to have endoscopic recurrence. A sensitivity
analysis excluding the Reinisch 2010 study found no statistically
significant difference between azathioprine and 5-aminosalicyclic
acid. A subgroup analysis by length of follow-up suggests a statis-
tically significant benefit for 5-aminosalicylates over purine ana-
logues at 12 months but not at 24 months. Seventy-six per cent of
patients in the antimetabolite group experienced a clinical relapse
at 12 months compared to 54% of 5-aminosalicylate patients (RR
1.40, 95% CI 1.12 to 1.74; 2 studies, 157 patients). However, a
high degree of heterogeneity was detected for this comparison (P
= 0.04, I2 = 77%). A sensitivity analysis removing the Reinisch
2010 study found no statistically significant difference in clinical
relapse rates between purine analogues and 5-aminosalicyclic acid
at 12 months follow-up.
There are considerable concerns raised with the safety profile
of azathioprine and 6-mercaptopurine. Adverse events requiring
medication to be discontinued were significantly more common
in the purine analogue group compared to 5-aminosalicylic acid.
One small study (n = 22) compared azathioprine to infliximab
and found no statistically significant differences in clinical relapse,
endoscopic relapse or withdrawal due to adverse events (Armuzzi
2013). Savarino 2013 (n = 33) compared azathioprine to adali-
mumab and found statistically significant differences in clinical
and endoscopic relapse favouring adalimumab over azathioprine.
The results of these studies should be interpreted with caution due
to the small number of patients.
Overall completeness and applicability of
evidence
We consider the evidence from this review to be applicable to most
patients with post-surgical remission of CD. However, the evi-
dence base cannot be considered to be complete. This review has
found a relatively small evidence base for the use of purine ana-
logues in the maintenance of surgically-induced remission in CD,
despite the widespread use of such medications in this setting. The
two studies (n = 168 participants) comparing azathioprine or 6-
mercaptopurine with placebo had significant clinical and method-
ological heterogeneity regarding the choice of purine analogue and
the use of concurrent medications. There was considerable clinical
and methodological heterogeneity across the five studies (n = 425
patients) that compared azathioprine or 6-mercaptopurine to 5-
aminosalicylic acid. Most of the trials were relatively small and
probably lacked sufficient power to detect any differences between
intervention groups. One small study compared azathioprine to
infliximab (n = 22) and one small study compared azathioprine to
adalimumab. Therefore, the evidence base can clearly be seen as
lacking.
Quality of the evidence
Four studies were judged to be at high risk of bias for blinding due
to open-label (Ardizzone 2004; Armuzzi 2013; Savarino 2013),
and single-blind design (D’Haens 2008). The results of the in-
cluded studies need to be interpreted with caution as GRADE
analyses rated the overall quality of the evidence for the primary
outcomes (i.e. clinical relapse or endoscopic relapse) as low or very
low due to high risk of bias (i.e. open-label or single-blind studies),
heterogeneity and imprecision (i.e. very sparse data) (See Summary
of findings 2; Summary of findings for the main comparison;
Summary of findings 3; Summary of findings 4).
Potential biases in the review process
We attempted to reduce potential biases in the review process.
A comprehensive literature search was performed to identify all
eligible studies. Two review authors independently assessed studies
for inclusion, extracted data and assessed study quality.
All analyses were completed using the intention-to-treat princi-
ple, whereby patients with final missing outcomes were assumed
to have relapsed. Given the high attrition rate in the purine ana-
logue groups compared to the 5-aminosalicylate groups, this may
have affected the difference in clinical relapse rates between purine
analogues and 5-aminosalicylates. However, it is arguably a moot
point given that even if purine analogues do have superior efficacy,
it is difficult to rationalise the use on the basis of the poor adverse
event profile in the published evidence.
Agreements and disagreements with other
studies or reviews
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A recent Cochrane review assessing the use of azathioprine or 6-
mercaptopurine for maintenance of medically-induced remission
in CD disease revealed that the purine analogues are more effective
than placebo, with higher response rates for azathioprine than 6-
mercaptopurine (Prefontaine 2009). These findings are mirrored
in the two studies comparing purine analogues to placebo. No
difference in efficacy was found between azathioprine or 6-mer-
captopurine and 5-aminosalicylic acid. This could be due to lower
disease activity following resection of the gut than is achieved in
medically-induced remission of CD, so that a milder anti-inflam-
matory agent such as 5-aminosalicylic acid, gives a better risk ver-
sus benefit ratio when compared to azathioprine and 6-mercap-
topurine. It is also possible that the methodology of the included
studies supports this hypothesis, with all but one study recruit-
ing patients in the immediate post-surgical setting. As such, the
patients are potentially at their lowest period of disease activity
clinically and microscopically.
ACochrane review (Gordon 2011) looking at the use of 5-aminos-
alicylic acid for the maintenance of surgically-induced remission
in CD suggests that 5-aminosalicyclic acid may be superior to
placebo (Gordon 2011). It also showed that 5-aminosalicylic acid
is a safe and well tolerated drug, as the incidence of adverse events
was not different in patients receiving 5-aminosalicylic acid com-
pared to those receiving placebo. The results of this systematic
review question the risk versus benefit balance of starting a purine
analogue over 5-aminosalicylic acid in postoperative CD.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Purine analogues may be superior to placebo for maintenance of
surgically-induced remission in patients with CD. The results for
efficacy outcomes between purine analogues and 5-aminosalicylic
acid were uncertain. However, patients taking purine analogues
weremore likely than 5-aminosalicylic acid patients to discontinue
therapy due to adverse events. These results question the use of
azathioprine and 6-mercaptopurine in patients with surgically-
induced remission of CD. No firm conclusions can be drawn from
the two small studies that compared azathioprine to infliximab or
adalimumab. Adalimumab may be superior to azathioprine but
further research is needed to confirm these results.There may be
a role for other agents for maintenance of post-surgical remission
in CD.
Implications for research
Using the GRADE criteria the overall quality of the evidence was
judged to be low for the placebo controlled studies and low or very
low for the active comparator studies.Therefore the strength of
our conclusions is extremely limited. Further research investigat-
ing the efficacy and safety of azathioprine and 6-mercaptopurine
in comparison to other active medications in patients with surgi-
cally-induced remission of CD is warranted. The use of TPMT
monitoring as part of such research protocols may be beneficial.
Only one of the five studies mentioned the use of TPMT mon-
itoring which may be important in identifying patients who are
more likely to tolerate azathioprine and 6-mercaptopurine. There
could be a role for TMPT monitoring when weighing the risk
versus benefit of using purine analogues, and future research could
incorporate this.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ardizzone 2004
Methods Open-label, single-centre, randomised, controlled trial
Participants Crohn’s disease patients were enrolled 2 weeks after elective stricturoplasty, minimal
bowel resection or both (N = 142)
Exclusion criteria included contraindications for use of azathioprine or mesalamine; sig-
nificant preexisting conditions; the use of immunosuppressive drugs in the past 3months
or anti-tumour necrosis factor within the 6 months before surgery; any corticosteroid-
dependant disease; as well as women who were pregnant, planning pregnancy or breast-
feeding
Interventions Azathioprine 2 mg/kg/day (n = 71) for 24 months or until relapse
Mesalamine 3 g/day (n = 71) for 24 months or until relapse
Outcomes Primary outcomes: clinical relapse (symptoms of active disease with laboratory, radio-
logical or endoscopic findings and CDAI > 200 to warrant steroids) or surgical relapse
(symptoms refractory to medical treatment and need for further surgery) at 24 months
Secondary outcome: adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation in
blocks of 10
Allocation concealment (selection bias) Unclear risk Not clearly described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear with data reported
Selective reporting (reporting bias) Unclear risk Unclear with data reported
Other bias Low risk None apparent
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Armuzzi 2013
Methods Open-label, single-centre, randomised, controlled pilot study
Participants Consecutive Crohn’s disease patients who underwent a curative ileocolonic resection and
were considered to be at ’high risk’ of postoperative recurrence (N = 22)
Exclusion criteria: active perianal disease, presence of stoma, adverse events during pre-
vious therapy with infliximab or azathioprine, age > 70 years, surgical complications,
active infectious diseases, history of cancer, renal, cardiac or hepatic failure, history of
acute or chronic
pancreatitis, severe leucopenia and pregnancy
Interventions Infliximab 5 mg/kg at weeks 0, 2 and 6 weeks and then every 8 weeks for 1 year (n = 11)
Azathioprine 2.5 mg/kg/day for 1 year (n =11)
All patients received oral metronidazole (500 mg twice daily) for 2 weeks after surgery
Treatment was started within 2 to 4 weeks of surgery
No other drugs were allowed
Outcomes Co-primary outcomes were endoscopic, histological and clinical recurrence at 12months
Secondary outcomes: Harvey-Bradshaw Index, laboratory tests and adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient in the azathioprine group
withdrewdue to adverse events (severe nau-
sea and epigastric pain), no other patients
withdrew
Selective reporting (reporting bias) Low risk Appropriate data reported
Other bias Low risk None apparent
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D’Haens 2008
Methods Randomised controlled trial at 2 centres
Participants Adult CD patients were enrolled within 2 weeks of curative ileal or ileocolonic resection
with ileocolonic anastomosis (N = 81)
Exclusion criteria: Patients with macroscopic evidence of pancolitis or disease proximal
or distal to the site of resection or those who had an ileorectal anastomosis or stoma,
contraindications for use of azathioprine or metronidazole; alcohol or drug abuse, leu-
copenia, malignancies or ongoing infectious disease (hepatitis, tuberculosis, AIDS); the
use of azathioprine within 2 months of surgery and pregnancy
Interventions Azathioprine 100 mg/day if patient weight was < 60 kg or 150 mg/day if patient weight
was > 60 kg (n= 40) for 12 months (n = 40)
Placebo for 12 months (n = 41)
All patients received metronidazole 250 mg three times daily or ornidazole 500 mg twice
daily for 3 months
Outcomes Primary outcome: proportion of patients with endoscopic recurrence (> 2 Rutgeers
endoscopic score) at 3 and 12 months
Secondary outcomes: clinical relapse (CDAI > 250), the severity of endoscopic recurrence
and adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Centralized pharmacy randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind: azathioprine dummy was pro-
vided in sealed containers so the investigator
did not see the pills
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full data reported
Selective reporting (reporting bias) Low risk Appropriate data reported
Other bias Low risk None apparent
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Hanauer 2004
Methods Randomised, multi-centre double-blind, double-dummy, controlled trial
Participants CD patients before postoperative hospital discharge after ileocolic resection with a pri-
mary anastomosis for disease confined to the ileum and adjacent colon (N = 131)
Patients were excluded if there was evidence of disease proximal or distal to the site of
resection
Interventions 6-mercaptopurine 50 mg/day for 24 months (n = 47)
mesalamine 3 g/day for 24 months (n = 44)
placebo for 24 months (n = 40)
Outcomes Primary outcomes: clinical relapse (score of > 2 on the clinical recurrence grading scale)
at 6, 12 and 24months, radiographic relapse (a score of > 2 on the radiological recurrence
grading scale) or endoscopic recurrence (score of > 2 on the Rutgeerts endoscopic scoring
system) at 12 and 24 months
Secondary outcome: adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation in blocks of 6
Allocation concealment (selection bias) Low risk Centralized pharmacy randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Identical matching placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full data reported
Selective reporting (reporting bias) Low risk Appropriate data reported
Other bias Low risk None apparent
Herfarth 2006
Methods Randomised, double-blind, double-dummy, multi-centre trial
Participants CD patients were enrolled within 2 weeks of surgery (N = 79)
Patients with homozygous TPMT deficiency were excluded
Interventions Azathioprine 2 to 2.5 mg/kg/day for 12 months (n = 42)
5-ASA 4 g/day for 12months (n = 37)
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Herfarth 2006 (Continued)
Outcomes Primary outcome: treatment failure endpointwas 12months clinical relapse (not defined)
or endoscopic relapse (not defined) or withdrawal due to any relapse or adverse event.
treatment failure: severe endoscopic relapse, withdrawal due to clinical relapse or adverse
drug reaction
Notes Ended prematurely because an interim analysis revealed that the hypothesis of superiority
of AZA versus 5-ASA could not be tested with the planned sample size
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Centralized randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full data reported
Selective reporting (reporting bias) Low risk Appropriate data reported
Other bias Low risk None apparent
Reinisch 2010
Methods Randomised, double-blind, double-dummy, multi-centre trial
Participants CD patients within 6 to 24 months of resection with a ileocolonic anastomosis who
had no clinical recurrence with CDAI < 200 but with moderate or severe endoscopic
recurrence
Exclusion criteria: short bowel syndrome, stricture plasty or an ileocolonic stoma, TPMT
deficiency; high serum creatinine; or the use of immunosuppressants or anti-tumour
necrosis factor since resection, corticosteroids or oral antibiotics for > 4weeks since
resection, or NSAIDs within the preceding 2 weeks
Interventions Azathioprine 2 to 2.5 mg/kg/day for 12 months (n = 41)
Mesalazine 4 g/day for 12 months (n = 37)
Outcomes Primary outcome: clinical relapse (CDAI > 200 and an increase of > 60 points from
baseline) at 12 months or withdrawal due to any relapse or adverse event
Secondary outcomes: endoscopic improvement (>1 point reduction in Rutgeerts score)
or any change in CDAI score, IBDQ score and CRP level from baseline
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Reinisch 2010 (Continued)
Notes Included despite endoscopic recurrence as inclusion criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation in blocks of 4
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full data reported
Selective reporting (reporting bias) Low risk Appropriate data reported
Other bias Low risk None apparent although funded by drug
company and some authors employed by
drug company
Savarino 2013
Methods Open-label, randomised, controlled trial
Participants Adult patients with ileal or ileocolonic CD undergoing resection (N = 51)
Exclusion criteria: more than 10 years of Crohn’s disease requiring first resection for
short (10 cm) fibrostenotic stricture, macroscopically active disease not resected during
surgery, or the presence of a stoma
Interventions Adalimumab 160/80 mg at weeks 0 and 2, followed by 40 mg every 2 weeks for 2 years
(n = 16)
Azathioprine 2.0 mg/kg/day for 2 years (n = 17)
Mesalamine 3 g/day for 2 years (n = 18)
Outcomes Primary outcome: the proportion of patients with endoscopic and clinical recurrence at
2 years
Secondary outcomes: quality of life (IBD-Q), adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Savarino 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk “Patient allocation was concealed and per-
formed by an independent nurse not in-
volved with the trial”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient withdrew from the adalimumab
group due to atopic dermatitis
Two patients withdrew from the azathio-
prine group due to a severe exacerbation of
Crohn’s disease or an adverse event (severe
abdominal pain and increase of pancreatic
enzymes
Two patients withdrew from the 5-ASA
group due to severe exacerbation of Crohn’s
disease
Selective reporting (reporting bias) Low risk Appropriate data reported
Other bias Low risk None apparent
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ferrante 2014 Abstract publication
All patients received azathioprine
Study compared systematic azathioprine therapy to endoscopically driven azathioprine therapy
Mañosa 2013 All patients received azathioprine
Study compared combination of azathioprine and metronidazole to azathioprine
Nos 2000 Not RCT after contacting author
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D A T A A N D A N A L Y S E S
Comparison 1. Azathioprine or 6-mercaptopurine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse (fixed-effect) 2 168 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.58, 0.94]
2 Clinical relapse, sensitivity
analysis, (random-effects)
2 168 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.61, 0.95]
3 Endoscopic relapse (fixed-effect) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Adverse events requiring
withdrawal (fixed-effect)
2 168 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.59, 2.98]
Comparison 2. Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse (fixed-effect) 5 425 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.99, 1.34]
2 Clinical relapse,sensitivity
analysis (random-effects)
5 425 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.93, 1.41]
3 Clinical relapse, sensitivity
analysis excluding study
that enrolled patients with
endoscopic recurrence,
(fixed-effect)
4 347 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.91, 1.24]
4 Clinical relapse, subgroup
analysis by drug type
(fixed-effect)
5 425 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.99, 1.34]
4.1 Azathioprine 4 334 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.04, 1.51]
4.2 6-mercaptopurine 1 91 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.70, 1.18]
5 Clinical relapse, subgroup
analysis by length of follow-up
5 425 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.99, 1.34]
5.1 12 months 2 157 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.12, 1.74]
5.2 24 months 3 268 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.81, 1.24]
6 Endoscopic relapse (fixed-effect) 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Adverse events (fixed-effect) 4 334 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.93, 1.27]
8 Adverse events requiring
withdrawal (fixed-effect)
5 423 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [1.26, 3.39]
9 Adverse events requiring
withdrawal, subgroup analysis
by drug type (fixed-effect)
5 423 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [1.26, 3.39]
9.1 Azathioprine 4 332 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [1.31, 4.22]
9.2 6-mercaptopurine 1 91 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.54, 3.62]
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10 Serious adverse events
(random-effects)
2 169 Risk Ratio (M-H, Random, 95% CI) 2.61 [0.04, 162.02]
Comparison 3. Azathioprine versus infliximab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Endoscopic relapse 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Adverse events requiring
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Azathioprine versus adalimumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Endoscopic relapse 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Adverse events requiring
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 1 Clinical relapse
(fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 1 Clinical relapse (fixed-effect)
Study or subgroup AZA/6MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
D’Haens 2008 10/40 16/41 29.5 % 0.64 [ 0.33, 1.24 ]
Hanauer 2004 32/47 35/40 70.5 % 0.78 [ 0.62, 0.98 ]
Total (95% CI) 87 81 100.0 % 0.74 [ 0.58, 0.94 ]
Total events: 42 (AZA/6MP), 51 (Placebo)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AZA/6MP Favours Placebo
33Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 2 Clinical relapse,
sensitivity analysis, (random-effects).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 2 Clinical relapse, sensitivity analysis, (random-effects)
Study or subgroup AZA/6MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
D’Haens 2008 10/40 16/41 10.7 % 0.64 [ 0.33, 1.24 ]
Hanauer 2004 32/47 35/40 89.3 % 0.78 [ 0.62, 0.98 ]
Total (95% CI) 87 81 100.0 % 0.76 [ 0.61, 0.95 ]
Total events: 42 (AZA/6MP), 51 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AZA/6MP Favours Placebo
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Analysis 1.3. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 3 Endoscopic
relapse (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 3 Endoscopic relapse (fixed-effect)
Study or subgroup 6-MP Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hanauer 2004 8/47 17/40 0.40 [ 0.19, 0.83 ]
0.01 0.1 1 10 100
Favours 6-MP Favours Placebo
Analysis 1.4. Comparison 1 Azathioprine or 6-mercaptopurine versus placebo, Outcome 4 Adverse events
requiring withdrawal (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 Azathioprine or 6-mercaptopurine versus placebo
Outcome: 4 Adverse events requiring withdrawal (fixed-effect)
Study or subgroup AZA/6MP Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
D’Haens 2008 4/40 5/41 53.3 % 0.82 [ 0.24, 2.84 ]
Hanauer 2004 9/47 4/40 46.7 % 1.91 [ 0.64, 5.75 ]
Total (95% CI) 87 81 100.0 % 1.33 [ 0.59, 2.98 ]
Total events: 13 (AZA/6MP), 9 (Placebo)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AZA/6MP Favours Placebo
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Analysis 2.1. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 1
Clinical relapse (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 1 Clinical relapse (fixed-effect)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardizzone 2004 31/71 30/71 26.0 % 1.03 [ 0.71, 1.51 ]
Hanauer 2004 32/47 33/44 29.6 % 0.91 [ 0.70, 1.18 ]
Herfarth 2006 39/42 29/37 26.8 % 1.18 [ 0.98, 1.43 ]
Reinisch 2010 24/41 11/37 10.0 % 1.97 [ 1.13, 3.44 ]
Savarino 2013 11/17 9/18 7.6 % 1.29 [ 0.72, 2.31 ]
Total (95% CI) 218 207 100.0 % 1.15 [ 0.99, 1.34 ]
Total events: 137 (AZA/6-MP), 112 (5-ASA)
Heterogeneity: Chi2 = 7.31, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
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Analysis 2.2. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 2
Clinical relapse,sensitivity analysis (random-effects).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 2 Clinical relapse,sensitivity analysis (random-effects)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ardizzone 2004 31/71 30/71 18.3 % 1.03 [ 0.71, 1.51 ]
Hanauer 2004 32/47 33/44 27.1 % 0.91 [ 0.70, 1.18 ]
Herfarth 2006 39/42 29/37 34.0 % 1.18 [ 0.98, 1.43 ]
Reinisch 2010 24/41 11/37 10.6 % 1.97 [ 1.13, 3.44 ]
Savarino 2013 11/17 9/18 10.0 % 1.29 [ 0.72, 2.31 ]
Total (95% CI) 218 207 100.0 % 1.14 [ 0.93, 1.41 ]
Total events: 137 (AZA/6-MP), 112 (5-ASA)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.31, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
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Analysis 2.3. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 3
Clinical relapse, sensitivity analysis excluding study that enrolled patients with endoscopic recurrence, (fixed-
effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 3 Clinical relapse, sensitivity analysis excluding study that enrolled patients with endoscopic recurrence, (fixed-effect)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardizzone 2004 31/71 30/71 28.9 % 1.03 [ 0.71, 1.51 ]
Hanauer 2004 32/47 33/44 32.9 % 0.91 [ 0.70, 1.18 ]
Herfarth 2006 39/42 29/37 29.7 % 1.18 [ 0.98, 1.43 ]
Savarino 2013 11/17 9/18 8.4 % 1.29 [ 0.72, 2.31 ]
Total (95% CI) 177 170 100.0 % 1.06 [ 0.91, 1.24 ]
Total events: 113 (AZA/6-MP), 101 (5-ASA)
Heterogeneity: Chi2 = 3.18, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
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Analysis 2.4. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 4
Clinical relapse, subgroup analysis by drug type (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 4 Clinical relapse, subgroup analysis by drug type (fixed-effect)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azathioprine
Ardizzone 2004 31/71 30/71 26.0 % 1.03 [ 0.71, 1.51 ]
Herfarth 2006 39/42 29/37 26.8 % 1.18 [ 0.98, 1.43 ]
Reinisch 2010 24/41 11/37 10.0 % 1.97 [ 1.13, 3.44 ]
Savarino 2013 11/17 9/18 7.6 % 1.29 [ 0.72, 2.31 ]
Subtotal (95% CI) 171 163 70.4 % 1.25 [ 1.04, 1.51 ]
Total events: 105 (AZA/6-MP), 79 (5-ASA)
Heterogeneity: Chi2 = 3.85, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.35 (P = 0.019)
2 6-mercaptopurine
Hanauer 2004 32/47 33/44 29.6 % 0.91 [ 0.70, 1.18 ]
Subtotal (95% CI) 47 44 29.6 % 0.91 [ 0.70, 1.18 ]
Total events: 32 (AZA/6-MP), 33 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 218 207 100.0 % 1.15 [ 0.99, 1.34 ]
Total events: 137 (AZA/6-MP), 112 (5-ASA)
Heterogeneity: Chi2 = 7.31, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Chi2 = 3.88, df = 1 (P = 0.05), I2 =74%
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
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Analysis 2.5. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 5
Clinical relapse, subgroup analysis by length of follow-up.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 5 Clinical relapse, subgroup analysis by length of follow-up
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Herfarth 2006 39/42 29/37 26.8 % 1.18 [ 0.98, 1.43 ]
Reinisch 2010 24/41 11/37 10.0 % 1.97 [ 1.13, 3.44 ]
Subtotal (95% CI) 83 74 36.8 % 1.40 [ 1.12, 1.74 ]
Total events: 63 (AZA/6-MP), 40 (5-ASA)
Heterogeneity: Chi2 = 4.41, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 2.98 (P = 0.0029)
2 24 months
Ardizzone 2004 31/71 30/71 26.0 % 1.03 [ 0.71, 1.51 ]
Hanauer 2004 32/47 33/44 29.6 % 0.91 [ 0.70, 1.18 ]
Savarino 2013 11/17 9/18 7.6 % 1.29 [ 0.72, 2.31 ]
Subtotal (95% CI) 135 133 63.2 % 1.01 [ 0.81, 1.24 ]
Total events: 74 (AZA/6-MP), 72 (5-ASA)
Heterogeneity: Chi2 = 1.34, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 218 207 100.0 % 1.15 [ 0.99, 1.34 ]
Total events: 137 (AZA/6-MP), 112 (5-ASA)
Heterogeneity: Chi2 = 7.31, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Chi2 = 4.48, df = 1 (P = 0.03), I2 =78%
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
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Analysis 2.6. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 6
Endoscopic relapse (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 6 Endoscopic relapse (fixed-effect)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hanauer 2004 8/47 21/44 0.36 [ 0.18, 0.72 ]
Savarino 2013 11/17 15/18 0.78 [ 0.52, 1.17 ]
0.1 0.2 0.5 1 2 5 10
Favours AZA/6-MP Favours 5-ASA
Analysis 2.7. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 7
Adverse events (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 7 Adverse events (fixed-effect)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardizzone 2004 28/71 18/71 19.0 % 1.56 [ 0.95, 2.55 ]
Herfarth 2006 29/42 26/37 29.2 % 0.98 [ 0.73, 1.32 ]
Reinisch 2010 34/41 32/37 35.5 % 0.96 [ 0.79, 1.16 ]
Savarino 2013 15/17 16/18 16.4 % 0.99 [ 0.78, 1.26 ]
Total (95% CI) 171 163 100.0 % 1.08 [ 0.93, 1.27 ]
Total events: 106 (AZA/6-MP), 92 (5-ASA)
Heterogeneity: Chi2 = 4.67, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 8
Adverse events requiring withdrawal (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 8 Adverse events requiring withdrawal (fixed-effect)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ardizzone 2004 15/71 6/71 29.1 % 2.50 [ 1.03, 6.07 ]
Hanauer 2004 9/47 6/44 30.1 % 1.40 [ 0.54, 3.62 ]
Herfarth 2006 7/42 4/37 20.6 % 1.54 [ 0.49, 4.85 ]
Reinisch 2010 11/41 2/37 10.2 % 4.96 [ 1.18, 20.94 ]
Savarino 2013 2/17 2/16 10.0 % 0.94 [ 0.15, 5.91 ]
Total (95% CI) 218 205 100.0 % 2.07 [ 1.26, 3.39 ]
Total events: 44 (AZA/6-MP), 20 (5-ASA)
Heterogeneity: Chi2 = 3.19, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 9
Adverse events requiring withdrawal, subgroup analysis by drug type (fixed-effect).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 9 Adverse events requiring withdrawal, subgroup analysis by drug type (fixed-effect)
Study or subgroup AZA 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azathioprine
Ardizzone 2004 15/71 6/71 29.1 % 2.50 [ 1.03, 6.07 ]
Herfarth 2006 7/42 4/37 20.6 % 1.54 [ 0.49, 4.85 ]
Reinisch 2010 11/41 2/37 10.2 % 4.96 [ 1.18, 20.94 ]
Savarino 2013 2/17 2/16 10.0 % 0.94 [ 0.15, 5.91 ]
Subtotal (95% CI) 171 161 69.9 % 2.35 [ 1.31, 4.22 ]
Total events: 35 (AZA), 14 (5-ASA)
Heterogeneity: Chi2 = 2.53, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
2 6-mercaptopurine
Hanauer 2004 9/47 6/44 30.1 % 1.40 [ 0.54, 3.62 ]
Subtotal (95% CI) 47 44 30.1 % 1.40 [ 0.54, 3.62 ]
Total events: 9 (AZA), 6 (5-ASA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 218 205 100.0 % 2.07 [ 1.26, 3.39 ]
Total events: 44 (AZA), 20 (5-ASA)
Heterogeneity: Chi2 = 3.19, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Chi2 = 0.83, df = 1 (P = 0.36), I2 =0.0%
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Analysis 2.10. Comparison 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid, Outcome 10
Serious adverse events (random-effects).
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 Azathioprine or 6-mercaptopurine versus 5-aminosalicylic acid
Outcome: 10 Serious adverse events (random-effects)
Study or subgroup AZA/6-MP 5-ASA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanauer 2004 0/47 1/44 48.4 % 0.31 [ 0.01, 7.47 ]
Reinisch 2010 10/41 0/37 51.6 % 19.00 [ 1.15, 313.35 ]
Total (95% CI) 88 81 100.0 % 2.61 [ 0.04, 162.02 ]
Total events: 10 (AZA/6-MP), 1 (5-ASA)
Heterogeneity: Tau2 = 6.56; Chi2 = 3.81, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours AZA/6-MP
Analysis 3.1. Comparison 3 Azathioprine versus infliximab, Outcome 1 Clinical relapse.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine versus infliximab
Outcome: 1 Clinical relapse
Study or subgroup Azathioprine Infliximab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armuzzi 2013 2/11 1/11 2.00 [ 0.21, 18.98 ]
0.01 0.1 1 10 100
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Analysis 3.2. Comparison 3 Azathioprine versus infliximab, Outcome 2 Endoscopic relapse.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine versus infliximab
Outcome: 2 Endoscopic relapse
Study or subgroup Azathioprine Infliximab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armuzzi 2013 4/10 1/11 4.40 [ 0.59, 33.07 ]
0.01 0.1 1 10 100
Favours azathioprine Favours infliximab
Analysis 3.3. Comparison 3 Azathioprine versus infliximab, Outcome 3 Adverse events requiring
withdrawal.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 Azathioprine versus infliximab
Outcome: 3 Adverse events requiring withdrawal
Study or subgroup Azathioprine Infliximab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armuzzi 2013 1/11 0/11 3.00 [ 0.14, 66.53 ]
0.01 0.1 1 10 100
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Analysis 4.1. Comparison 4 Azathioprine versus adalimumab, Outcome 1 Clinical relapse.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 Azathioprine versus adalimumab
Outcome: 1 Clinical relapse
Study or subgroup Azathioprine Adalimumab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 11/17 2/16 5.18 [ 1.35, 19.83 ]
0.02 0.1 1 10 50
Favours azathioprine Favours adalimumab
Analysis 4.2. Comparison 4 Azathioprine versus adalimumab, Outcome 2 Endoscopic relapse.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 Azathioprine versus adalimumab
Outcome: 2 Endoscopic relapse
Study or subgroup Azathioprine Adalimumab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 11/17 1/16 10.35 [ 1.50, 71.32 ]
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Analysis 4.3. Comparison 4 Azathioprine versus adalimumab, Outcome 3 Adverse events.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 Azathioprine versus adalimumab
Outcome: 3 Adverse events
Study or subgroup Azathioprine Adalimumab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 15/17 11/16 1.28 [ 0.88, 1.86 ]
0.1 0.2 0.5 1 2 5 10
Favours azathioprine Favours adalimumab
Analysis 4.4. Comparison 4 Azathioprine versus adalimumab, Outcome 4 Adverse events requiring
withdrawal.
Review: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 Azathioprine versus adalimumab
Outcome: 4 Adverse events requiring withdrawal
Study or subgroup Azathioprine Adalimumab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savarino 2013 2/17 1/16 1.88 [ 0.19, 18.80 ]
0.02 0.1 1 10 50
Favours azathioprine Favours adalimumab
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A P P E N D I C E S
Appendix 1. Search Strategies
PubMed
#1 crohn* OR IBD OR “inflammatory bowel disease” OR regional enteritis OR ileitis
# 2 singl* OR doubl* OR tripl* OR trebl* OR blind* OR mask* OR placebo* OR single-blind* OR double-blind* OR triple-blind*
OR random* OR (controlled clinical)
# 3 #1 AND # 2
# 4 AZA or azathioprine
# 5 6-mercaptopurine or mercaptopurine or 6-MP or 6MP
# 6 anti-metabolite* or antimetabolite*
# 7 #4 OR #5 OR #6
# 8 #3 AND #7
# 9 surgery or surgic* or post-surgical or post-surgery or postoperative or post-operative or resection or operation
# 10 #8 AND #9
MEDLINE
1 random$.tw.
2 factorial$.tw.
3 (crossover$ or cross over$ or cross-over$).tw.
4 placebo$.tw.
5 single blind.mp.
6 double blind.mp.
7 triple blind.mp.
8 (singl$ adj blind$).tw.
9 (double$ adj blind$).tw.
10 (tripl$ adj blind$).tw.
11 assign$.tw.
12 allocat$.tw.
13 crossover procedure/
14 double blind procedure/
15 single blind procedure/
16 triple blind procedure/
17 randomized controlled trial/
18 or/1-17
19. exp Crohn disease/ or crohn*.mp.
20. inflammatory bowel disease.mp.
21. IBD.mp.
22. 19 or 20 or 21
23. 18 and 22
24. azathioprine.mp. or exp azathioprine derivative/ or exp azathioprine/
25. 6-mercaptopurine.mp. or exp mercaptopurine/
26. (AZA or 6-MP or 6MP).mp.
27. exp antimetabolite/ or anti-metabolite*.mp.
28. antimetabolite*.mp.
29. 24 or 25 or 26 or 27 or 28
30. 23 and 29
31. surgery.mp. or surgery/
32. (surgical or surgically).mp.
33. surgic*.mp.
34. (post-surgical or post-surgery).mp.
35. (postoperative or post-operative).mp.
36. resection.mp. or surgery/
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37. operation.mp. or surgery/
38. 31 or 32 or 33 or 34 or 35 or 36 or 37
39. 30 and 38
EMBASE
1 random$.tw.
2 factorial$.tw.
3 (crossover$ or cross over$ or cross-over$).tw.
4 placebo$.tw.
5 single blind.mp.
6 double blind.mp.
7 triple blind.mp.
8 (singl$ adj blind$).tw.
9 (double$ adj blind$).tw.
10 (tripl$ adj blind$).tw.
11 assign$.tw.
12 allocat$.tw.
13 crossover procedure/
14 double blind procedure/
15 single blind procedure/
16 triple blind procedure/
17 randomized controlled trial/
18 or/1-17
19. exp Crohn disease/ or crohn*.mp.
20. inflammatory bowel disease.mp.
21. IBD.mp.
22. 19 or 20 or 21
23. 18 and 22
24. azathioprine.mp. or exp azathioprine derivative/ or exp azathioprine/
25. 6-mercaptopurine.mp. or exp mercaptopurine/
26. (AZA or 6-MP or 6MP).mp.
27. exp antimetabolite/ or anti-metabolite*.mp.
28. antimetabolite*.mp.
29. 24 or 25 or 26 or 27 or 28
30. 23 and 29
31. surgery.mp. or surgery/
32. (surgical or surgically).mp.
33. surgic*.mp.
34. (post-surgical or post-surgery).mp.
35. (postoperative or post-operative).mp.
36. resection.mp. or surgery/
37. operation.mp. or surgery/
38. 31 or 32 or 33 or 34 or 35 or 36 or 37
39. 30 and 38
CENTRAL
#1 crohn* or “inflammatory bowel disease” or IBD
#2 anti-metabolite* or antimetabolite*
#3 6-mercaptopurine or mercaptopurine or 6-MP or 6MP
#4 AZA or azathioprine
#5 #2 or #3 or #4
# 6 #1 and #5
#7 surgery or surgic* or post-surgical or post-surgery or postoperative or post-operative or resection or operation
#8 #6 and #7
SR-IBD
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Crohn AND 6-mercaptopurine or 6-MP or 6MP or azathioprine AND surgery or surgic* or post* or resection or operation
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The following sensitivity analyses were planned but not carried out due to lack of data and small number of studies:
a. only including patients’ whose outcome was known i.e. number of patients who completed the study used as denominator;
b. allocation concealment;
c. dose of AZA/6-MP; and
d. concurrent medications (5-aminosalicylic acid and other concurrent immunosuppressants such as methotrexate, cyclosporine, my-
cophenolate mofetil, infliximab, or adalimumab).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
6-Mercaptopurine [∗therapeutic use]; Anti-InflammatoryAgents,Non-Steroidal [therapeutic use]; Antibodies,Monoclonal [therapeutic
use]; Antibodies,Monoclonal,Humanized [therapeutic use]; Azathioprine [∗ therapeutic use]; CrohnDisease [∗drug therapy; prevention
& control; surgery]; Immunosuppressive Agents [∗therapeutic use]; Maintenance Chemotherapy [∗methods]; Mesalamine [therapeutic
use]; Randomized Controlled Trials as Topic; Remission Induction [methods]; Secondary Prevention
MeSH check words
Humans
51Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
